UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

The lancet oncology, 2018-10, Vol.19 (10), p.1372-1384

2018

Volltextzugriff (PDF)

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

The Lancet (British edition), 2017-06, Vol.389 (10088), p.2492-2502

2017

Volltextzugriff (PDF)

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

The Lancet (British edition), 2023-05, Vol.401 (10389), p.1655-1668

2023

Volltextzugriff (PDF)

Gastrointestinal stromal tumours

Nature reviews. Disease primers, 2021-03, Vol.7 (1), p.22-22, Article 22

2021

Volltextzugriff (PDF)

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020-05, Vol.23 (3), p.510-519

2020

Volltextzugriff (PDF)

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

The lancet oncology, 2017-05, Vol.18 (5), p.640-653

2017

Volltextzugriff (PDF)

The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines

Gastric Cancer, 2016-01, Vol.19 (1), p.3-14

2016

Volltextzugriff (PDF)

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2017-12, Vol.390 (10111), p.2461-2471

2017

Volltextzugriff (PDF)

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

British journal of cancer, 2020-05, Vol.122 (11), p.1630-1637

2020

Volltextzugriff (PDF)

Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-05, Vol.22 (3), p.527-535

2019

Volltextzugriff (PDF)

EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

BMC cancer, 2019-05, Vol.19 (1), p.494-494, Article 494

2019

Volltextzugriff (PDF)

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

The lancet oncology, 2020-07, Vol.21 (7), p.935-946

2020

Volltextzugriff (PDF)

Management of gastric cancer in Asia: resource-stratified guidelines

The lancet oncology, 2013-11, Vol.14 (12), p.e535-e547

2013

Volltextzugriff (PDF)

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Journal of clinical oncology, 2011-10, Vol.29 (30), p.3968-3976

2011

Volltextzugriff (PDF)

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

The lancet oncology, 2022-12, Vol.23 (12), p.1558-1570

2022

Volltextzugriff (PDF)

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

The lancet oncology, 2022-11, Vol.23 (11), p.1430-1440

2022

Volltextzugriff (PDF)

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

Journal of hepatology, 2019-09, Vol.71 (3), p.543-552

2019

Volltextzugriff (PDF)

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4067-4075

2013

Volltextzugriff (PDF)

Perioperative FLOT: new standard for gastric cancer?

The Lancet (British edition), 2019-05, Vol.393 (10184), p.1914-1916

2019

Volltextzugriff (PDF)

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

The Lancet (British edition), 2010-08, Vol.376 (9742), p.687-697

2010

Volltextzugriff (PDF)

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

Journal of hepatology, 2017-06, Vol.66 (6), p.1166-1172

2017

Volltextzugriff (PDF)

Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients

Cancer, 2022-03, Vol.128 (5), p.995-1003

2022

Volltextzugriff (PDF)

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023-01, Vol.26 (1), p.123-131

2023

Volltextzugriff (PDF)

1 – 25 von 690

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(644)
Mit Volltextzugriff
(634)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(340)
Life Sciences & Biomedicine
(327)
Humans
(292)
Oncology
(249)
Female
(226)
Middle Aged
(225)
Male
(221)
Adult
(199)
Aged
(198)
Tumors
(113)
Stomach Neoplasms - Drug Therapy
(102)
Chemotherapy
(100)
Treatment Outcome
(96)
Gastric Cancer
(95)
Medicine
(87)
Medicine & Public Health
(85)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(83)
Biological And Medical Sciences
(82)
Medical Sciences
(79)
Cancer Research
(77)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Gastrointestinal stromal tumours

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

Management of gastric cancer in Asia: resource-stratified guidelines

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

Perioperative FLOT: new standard for gastric cancer?

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial

Suchergebnisse filtern